ArticleBMJ open quality2025
Reducing surgical site infections in patients undergoing pancreatic resection: a quality improvement initiative.
Article in BMJ open quality, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgical site infections (SSIs) represent a significant source of morbidity during pancreaticoduodenectomy. The use of piperacillin-tazobactam (pip-tazo) has been shown to significantly reduce the incidence of SSI in this patient population. We thus elected to perform a quality improvement (QI) project to reduce superficial and deep SSI rates by ensuring all patients received pip-tazo as antibiotic prophylaxis.
methodsWe collected baseline retrospective data on a historical cohort of patients undergoing pancreaticoduodenectomy or total pancreatectomy from 1 January 2022 to 31 December 2022. We then launched our QI project on 1 January 2023, consisting of a multidisciplinary team creation and numerous outreach activities. The project had two Plan, Do, Study, Act (PDSA) cycles and ran until April 2024. The Standards for Quality Improvement Reporting Excellence guidelines were used to report results.
resultsBaseline cohort data included 64 patients, with 32% receiving pip-tazo and 39% developing an SSI. During phase one of our QI project (1 January 2023-31 August 2023), 54 patients underwent surgery, 90.7% received pip-tazo and 27.8% developed an SSI. Those who had undergone preoperative biliary stenting had a higher SSI rate (46.9% vs 4.4%). We thus added a second SSI reduction measure to patients with biliary stents: the ringed wound protector. During the second phase of our QI project (1 September 2023-1 April 2024), 51 patients underwent surgery, 98.0% received pip-tazo and 65.0% had a wound protector placed. SSI rates in this group were 9.8%.
conclusionWe describe a QI project whereby we increased the rates of correct antibiotic dosing in patients undergoing pancreatectomy to 98.0%. Although pip-tazo reduced SSI rates, the addition of a ringed wound protector in patients at high risk further reduced rates of SSI. We thus suggest the use of pip-tazo and ringed wound protectors as an effective strategy to reduce SSI rates in patients undergoing pancreatectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.